News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Hit by Lower Lab Test Prices, Nation’s Clinical Pathology Laboratories Embark on Cost-Cutting Programs

Many hospital outreach lab programs are dealing with the double whammy of successive reductions in Medicare Part B Clinical Laboratory Test fees and a shrinking budget by their parent hospitals

Over the past 24 months, all the painful cuts to lab test prices have made depressing news. These decreases in the prices paid to clinical laboratories by the Medicare program and major private health insurers mean that labs in 2014 will have significantly less revenue, even as the volume of specimens to be tested increases.

The logical response by many medical laboratory  organizations has been to take active steps to decrease expenses. In fact, the price and revenue erosion experienced by labs of all sizes and types over the past two years is the reason why cutting unnecessary costs is now a primary management goal at clinical laboratories throughout the United States. (more…)

This Week in Houston, Clinical Laboratory Industry’s Largest Trade Show Provided a Look at New Diagnostic Technologies

Many IVD vendors are cautiously optimistic about the “state of the medical lab industry,” but recognize that declining reimbursement for lab tests is now harming many lab organizations

DATELINE: Houston, Texas—Once again, the American Association of Clinical Chemistry (AACC) and the American Society for Clinical Laboratory Science (ASCLS) attracted a large crowd for their joint annual meeting. And, as is true every year, the activity on the exhibit floor provides valuable insights about the state of the clinical laboratory.

Your Dark Daily editorial team was here all week and had conversations with many executives from in vitro diagnostic  (IVD) manufacturers, laboratory informatics vendors, and specialty test companies.

Nation’s Largest Trade Show for Medical Laboratory Vendors (more…)

Two Different Point-of-Care Test Devices for Malaria Show Why Emerging Technologies Can Be Disruptive to Clinical Pathology Laboratories

Separate research projects at University of Washington and in the United Kingdom are producing handheld diagnostic devices to accurately detect Malaria

Two new handheld, point-of-care test (POC) devices for malaria  could save millions of lives in third-world countries. At the same time, these POC devices may lead to inexpensive alternatives for diagnosing common diseases in developed nations as well.

Clinical laboratory test developers see a big opportunity in developing assays to detect Malaria. That is because an estimated 200 million cases of malaria are diagnosed annually, resulting in the death of about 100 million people each year.

Recently, two organizations released news about the specific testing devices they have developed to detect malaria. One group is at the University of Washington in Seattle, Washington. The other group is NanoMal, a biotechnology company located in the United Kingdom. (more…)

Johnson & Johnson Says It Is ‘Exploring All Options’ for Selling, or Spinning Off, Its Ortho Clinical Diagnostics Unit That Sells Clinical Laboratory Products

Any change of ownership in the fifth largest in vitro diagnostics company would represent a major development in the medical laboratory testing marketplace

Medical laboratory managers may see more consolidation in the in vitro diagnostics market if executives at Johnson & Johnson (NYSE: JNJ) decide to sell its Ortho Clinical Diagnostics (OCD) unit. This decision was announced earlier this week during J&J’s conference call to discuss its fourth quarter 2012 financial report.

Ortho Clinical Diagnostics is considered the fifth largest IVD company. Thus, any sale or spin-off of this $2 billion enterprise will be a significant development for the clinical laboratory and pathology testing industry. (more…)

Predicted Growth for In Vitro Diagnostics Markets Globally Signals Upward Trajectory in Medical Laboratory Business

Growth in global IVD markets is indicator of increasing demand for clinical laboratory and anatomic pathology testing

During the next 24 months, the global in vitro diagnostics (IVD) market is predicted to exceed $50-billion in revenues. However, this robust growth has an upside and a downside for the clinical laboratories and pathology groups that purchase IVD analyzers, reagents, and consumables.

In a recent story in about the IVD industry, Frost & Sullivan, a global consulting and research firm, made predictions in different segments of the IVD market. It won’t surprise pathologists and clinical laboratory managers that the two fastest-growing segments are molecular and tissue diagnostics. (more…)

;